Preclinical PK/efficacy data is incremental and does not change the binary clinical/regulatory risk profile. Monitor for IND/clinical trial announcements and capital raise requirements given the going-concern warning and minimal cash runway.
Price Chart
Executive Summary
PRF Technologies reported expanded preclinical data for PRF-110, showing comparable analgesic efficacy to approved benchmark ZYNRELEF with slower absorption and enhanced local tissue retention. The filing provides incremental positive preclinical de-risking for the lead candidate but no new financial data or clinical trial milestones, and the company remains a going-concern risk with a $4M market cap and no approved products.
Key Facts
- PRF-110 demonstrated comparable analgesic efficacy to ZYNRELEF (bupivacaine/meloxicam ER) in a porcine post-operative pain model using von Frey methodology
- PRF-110 exhibited slower absorption rate and higher local tissue retention (Cmax) versus ZYNRELEF, suggesting a more gradual, prolonged release profile
- PRF Technologies has a going-concern warning from its auditor as of its most recent 20-F, with $4.1M cash and a history of significant losses
- Company is pre-revenue clinical-stage, market cap approximately $4M
Financial Impact
No financial figures reported in this filing; company had $4.1M cash per prior 20-F filing with no new revenue disclosed
Risk Factors
- Preclinical data does not guarantee success in human clinical trials
- Company has a going-concern warning and will likely need to raise capital, diluting existing shareholders
- PRF-110 requires additional studies before any regulatory filing can be made
- Nasdaq listing risk given sub-$4M market cap and micro-cap volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003339 |
| Document: zk2635607.htm | 0001178913-26-003339 |
| Document: 0001178913-26-003339-index-headers.html | 0001178913-26-003339 |
| Document: 0001178913-26-003339-index.html | 0001178913-26-003339 |
| Document: 0001178913-26-003339.txt | 0001178913-26-003339 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 6-K | $0.7400 | awaiting T+60 | — | $0.7393 (−0.09%) |
Oct 23, 2026 3d ago | Press Release | $0.7400 | awaiting T+60 | — | $0.7393 (−0.09%) |
Sep 28, 2026 28d ago | 6-K | $0.9720 | awaiting T+60 | — | $0.7393 (−23.94%) |
Sep 24, 2026 4w ago | SC 13D | $0.9767 | awaiting T+60 | — | $0.7393 (−24.31%) |
Sep 16, 2026 5w ago | 6-K | $1.01 | awaiting T+60 | — | $0.7393 (−26.80%) |
Sep 4, 2026 7w ago | EFFECT | $0.9680 | awaiting T+60 | — | $0.7393 (+23.63%) |
Sep 3, 2026 7w ago | 6-K | $0.9792 | awaiting T+60 | — | $0.7393 (−24.50%) |
Sep 3, 2026 7w ago | Press Release | $0.9792 | awaiting T+60 | — | $0.7393 (−24.50%) |
Jul 27, 2026 13w ago | 6-K | $1.09 $0.7120 | ▼ −34.68% | ▼ −38.38% | $0.7393 (−32.17%) |
Jul 21, 2026 13w ago | 6-K | $1.20 $0.8180 | ▼ −31.83% | ▼ −35.81% | $0.7393 (−38.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers